Shelton Capital Management bought a new position in Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,054 shares of the company’s stock, valued at approximately $827,000.
A number of other hedge funds also recently added to or reduced their stakes in LLY. BlackRock Inc. raised its stake in Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the period. Dodge & Cox raised its stake in Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after acquiring an additional 5,964,955 shares during the period. Renaissance Technologies LLC raised its stake in Eli Lilly and by 91.1% during the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after acquiring an additional 2,714,505 shares during the period. Vanguard Group Inc. grew its holdings in Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Finally, Winslow Capital Management LLC grew its holdings in Eli Lilly and by 79.7% during the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares in the last quarter. 76.43% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock worth $53,399,536 in the last ninety days. 0.20% of the stock is owned by corporate insiders.
A number of equities research analysts have issued reports on the stock. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday. Jefferies Group restated a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research report on Thursday, August 31st. Leerink Swann lifted their target price on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Piper Jaffray Companies restated an “overweight” rating and issued a $105.00 price objective (up from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $90.25.
Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.55 during trading hours on Thursday, reaching $85.87. The company’s stock had a trading volume of 4,344,910 shares, compared to its average volume of 3,673,220. The stock has a market cap of $94,220.00, a PE ratio of 21.04, a P/E/G ratio of 1.89 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 12 month low of $66.39 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.88 EPS. analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 99.05%.
TRADEMARK VIOLATION NOTICE: This piece was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/10054-shares-in-eli-lilly-and-company-lly-acquired-by-shelton-capital-management-updated-updated.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.